Granite Point Capital Management’s MacroGenics MGNX Stock Holding History

Granite Point Capital Management’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-40,000	Closed	-$1.01M	–	132
2018 Q1	$1.01M	Sell	40,000 -900	-2%	-$21.9K	0.1%	59
2017 Q4	$777K	Hold	40,900	–	–	0.08%	68
2017 Q3	$756K	Buy	+40,900	New	+$708K	0.16%	65

Other funds holding MGNX

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Granite Point Capital Management's MGNX Position: Q2 2018 in Review

Granite Point Capital Management sold out of MacroGenics (MGNX) in Q2 2018, closing a stake of 40,000 shares — an estimated $1.01M sold.

Granite Point Capital Management first reported a position in MGNX in Q3 2017 and held it in 3 quarters. The position peaked at $1.01M in Q1 2018. 127 funds tracked by Wall St. Rank hold MGNX as of Q2 2018.

Granite Point Capital Management reported no remaining MacroGenics position as of Q2 2018 after selling out during the quarter.
Granite Point Capital Management sold 40,000 MacroGenics shares in Q2 2018, an estimated $1.01M.
Granite Point Capital Management first reported a position in MacroGenics in Q3 2017 and held it in 3 quarters.
Granite Point Capital Management's MacroGenics position peaked at $1.01M in Q1 2018.
127 funds tracked by Wall St. Rank held MacroGenics as of Q2 2018.

Based on Granite Point Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.